Trial reportNutrients2022
A Four-Probiotics Regimen Combined with A Standard Helicobacter pylori-Eradication Treatment Reduces Side Effects and Increases Eradication Rates.
Trial report in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 5 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- The Health Benefits of Probiotic Lactiplantibacillus plantarum: A Systematic Review and Meta-Analysis.Probiotics and antimicrobial proteins · 2025Pooled it
- Efficacy and safety ofFrontiers in cellular and infection microbiology · 2025Pooled it
- Efficacy and safety of probiotics combined with bismuth-containing quadruple therapy forFrontiers in microbiology · 2025Pooled it
- Global status and trends of gastric cancer and gastric microbiota research: a bibliometric analysis.Frontiers in microbiology · 2024Pooled it
- Pooled it
- Impact of Probiotic-Adjunctive Vonoprazan-Amoxicillin Dual Therapy on Gut Microbiota and Clinical Symptoms in Helicobacter pylori Eradication.Tissue engineering and regenerative medicine · 2026Trial
- AdjuvantMicrobiology spectrum · 2026Trial
- Vonoprazan-amoxicillin dual therapy combined with probiotics for Helicobacter pylori eradication: a prospective, multicenter, randomized controlled trial.BMC gastroenterology · 2026Trial
- Multistrain probiotics alleviate gastrointestinal symptoms during bismuth quadruple therapy forWorld journal of gastroenterology · 2025Trial
- Impact of supplementing Limosilactobacillus fermentum MN-LF23 on the eradication of Helicobacter pylori with 14-day standard quadruple therapy: a randomized, double-blind, placebo-controlled trial.Nutrition journal · 2025Trial
- Effectiveness and safety of vonoprazan and amoxicillin dual regimen with Saccharomyces boulardii supplements on eradication of Helicobacter pylori.BMC gastroenterology · 2024Trial
- A Four-Probiotic Regime to Reduce Surgical Site Infections in Multi-Trauma Patients.Nutrients · 2022Trial
- Probiotics modulate gastrointestinal microbiota afterFrontiers in immunology · 2022Trial
- State-of-the-Art Review on Probiotics, Synbiotics, and Microbial Metabolites: Molecular Mechanisms Shaping Host Immunity, Metabolic Health, and Chronic Disease Prevention.Molecular nutrition & food research · 2026Review
- Therapeutic Potential of Probiotics in the Modulation of Antibiotic Resistance inBiomedicines · 2026Review
- Beyond Antibiotics: Alternative Strategies TargetingExpert reviews in molecular medicine · 2026Review
- Update on the pathogenesis and clinical management ofWorld journal of gastrointestinal pathophysiology · 2025Review
- Alteration of serum levels of tumour necrosis factor-a (TNF-a), interleukin-6 (IL-6), C-reactive protein (CRP), gastrin (GAS) and motilin (MTL) after treatment in the Helicobacter pylori-positive gastric ulcer.Journal of medical biochemistry · 2025Article
- Therapeutic Role of Probiotics for the Treatment of Dyspepsia: A Review of the Literature.Neurogastroenterology and motility · 2025Review
- Novel chromogenic medium-based method for the rapid detection ofWorld journal of gastroenterology · 2025Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To establish whether the addition of probiotics to a globally accepted Helicobacter pylori (H. pylori)-eradication scheme may reduce the rates of side effects and increase the eradication rates. Methods. Prospective, randomized, placebo-controlled trial of patients receiving eradication therapy for H. pylori in the eight participating centers. All patients received a 10-day proton pump inhibitor containing non-bismuth quadruple therapeutic regimen for H. pylori eradication (omeprazole 20 mg, amoxycillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg all twice daily orally) and were randomized to receive either probiotics (group A) or placebo (group B). The probiotic used combined four probiotic strains, i.e., Lactobacillus Acidophilus, Lactiplantibacillus plantarum, Bifidobacterium lactis, and Saccharomyces boulardii. Results. Data were analyzed for 329 patients in group A and 335 patients in group B. Fifty six (17.0%) patients in group A and 170 (50.7%) patients in group B reported the occurrence of an H. pylori treatment-associated new symptom or the aggravation of a pre-existing symptom of any severity (p < 0.00001). H. pylori was successfully eradicated in 303 patients in group A (92.0%) and 291 patients in group B (86.8%), (p = 0.028). Conclusion: Adding probiotics to the 10-day concomitant non-bismuth quadruple H. pylori eradication regimen increases the eradication rate and decreases side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.